Novo Nordisk to build $100m purification plant in Denmark
Novo Nordisk will invest about DKK500m ($100m) to build a new R&D facility in Bagsv?rd, Denmark, in order to increase its drug development capacity.
The company said that the new purification facility will expand its capacity to produce active pharmaceutical ingredients (APIs) for a growing number of diabetes drugs under development.
The new facility, which will have a total area of 2,700m2, is expected to be fully operational by late 2016 and will be operated by CMC Supply (Chemistry, Manufacturing and Control Supply), a unit within Novo Nordisk R&D.
CMC Supply is focused in the development, production and formulation of all new protein and peptide processes in Novo Nordisk.
CMC Supply senior vice president Jesper Boving said the new purification pilot plant will significantly increase company’s capacity for
«It will create up to 35 new jobs over a
Initially, the project includes establishment of a pilot plant with one purification line and later the facility can be expanded to the double size to further increase the capacity.